McKesson Corporation

NYSE:MCK

Medical - Distribution

Healthcare
$1,084.43 -3.71%

-$28.96 today

Market cap
$125.21B
Beta
0.32
P/E (TTM)
19.3
EPS (TTM)
$39.00
Dividend yield
0.44%
52W Low $637.00High $999.00

Volume 0.67M

Average 1.03M

MCK Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

McKesson CorporationNYSE: MCK

Research & Development · Q1 FY2027 · quarter ended Jun 2026

Research & development remains negative

Q1 FY2027 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0. Over 3 fiscal years it compounded at +5.0% a year.

Context

  • Research & development amounted to 0.0% of revenue in FY2026, unchanged from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearMar 2026
$103M+13.2% YoY
LTMJun 2026
$0— YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+13.2%——
3-year CAGR+5.0%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2026
103M USD
Year-over-year change
+13.2%
4-year CAGR
+10.1%

Research & Development vs competitors

How MCK compares with its peers on the latest reported figures

  • MCK's LTM Jun 2026 research & development of $0 is the highest of the 4 companies compared; the peer median is $0.
  • Research & development amounts to 0.0% of revenue for MCK, versus a peer median of 0.0%.
MCK Competitors Peer median
Research & Development for MCK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MCKMcKesson CorporationLTM Jun 2026$0 —+5.0%0.0%
CORCencora, Inc.LTM Jun 2026$0 ——0.0%
CAHCardinal Health, Inc.LTM Sep 2026$0 ——0.0%
ACHAccendra Health, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding MCK) $0——0.0%

Competitors are the stored peer set for MCK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Revenue263.97B276.71B308.95B359.05B403.43B
Cost of Revenue251.32B264.84B296.75B346.57B388.88B
Gross Profit12.65B11.87B12.2B12.49B14.55B
Gross Margin4.8%4.3%3.9%3.5%3.6%
Research & Development70M89M77M91M103M
Selling, General & Admin9.86B7.33B8.2B8.02B(8.1B)
Operating Expenses9.93B7.42B8.28B8.11B8.1B
Depreciation & Amortization760M608M635M636M729M
EBITDA2.87B5.49B4.67B5.25B7.18B
EBITDA Margin1.1%2.0%1.5%1.5%1.8%
Operating Income2.72B4.45B3.93B4.37B6.45B
Operating Margin1.0%1.6%1.3%1.2%1.6%
Interest Income10M107M118M173M179M
Interest Expense178M248M243M256M247M
Other Income / Expenses(795M)177M(138M)(13M)(253M)
Income Before Tax1.93B4.63B3.79B4.36B6.2B
Pre-Tax Margin0.7%1.7%1.2%1.2%1.5%
Income Tax Expense636M905M629M878M1.1B
Net Income1.11B3.56B3B3.3B4.76B
Net Margin0.4%1.3%1.0%0.9%1.2%
EPS (Basic)7.3125.2322.5425.8638.55
EPS (Diluted)7.2325.0422.3925.7238.38
Weighted Avg Shares152.3M141.1M133.2M127.4M123.6M
Weighted Avg Shares (Diluted)154.1M142.2M134.1M128.1M124.1M

McKesson Corporation

NYSE:MCK

Intrinsic Alpha fair value

Locked

Current Price

$1,084.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.